MedTrace Logo

Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia

NCT00383396 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2007-02-13

No results posted yet for this study

Summary

To Determine if topical cyclosporine 0.05% BID prevents recurrent inflammation and improves comfort in eyes with pterygia.

Conditions

  • Pterygia

Interventions

DRUG

Topical Cyclosporine

Sponsors & Collaborators

  • Innovative Medical

    lead INDUSTRY

Principal Investigators

  • Barry Schechter, MD · Florida Eye Microsurgical Institute

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00383396 on ClinicalTrials.gov